We’re ready to catch the quietest thief.
You could be going blind right now and have no idea. Most eye diseases quietly develop in your retina — without symptoms. That’s why routine screening is critical — to catch diseases early. Early enough to prevent eye diseases from stealing your vision. Another problem: the leading eye disease imaging technology, Optical Coherence Tomography (OCT), has been too expensive for most eyecare providers. Only the privileged few have had access to OCT systems worldwide.
IF DETECTED EARLY
What is OCT?
Optical Coherence Tomography is the light-equivalent to SONAR, sending signals to, then reflecting off of surfaces in order to measure depths of individual layers. Those collective signal measurements form an image of the retinal layers, where eye diseases quietly lurk, and can be accurately detected. Although OCT has been available for over 25 years, it remains an expensive technology to manufacture and operate. The use of high-quality optics, precision components and complex software have put this technology out of reach for most healthcare providers worldwide.
Affordable OCT is on its way.
Based on a breakthrough achieved by Dr. Adam Wax and his team at Duke University’s BIOS Lab, a patent-pending, low-cost, light-weight system has been devised that will revolutionize eye disease detection. Soon, more patients around the world will be able to have their retinas checked thanks to an affordable, portable OCT instrument. The Lumedica system is small, powerful and simple, it can be deployed as a stand-alone screening instrument, integrated with an Artificial-Intelligence data diagnostic, or as the front line of an eye care network.
Screening devices built by Lumedica Vision will go a long way toward reaching healthcare’s “triple aim.” For many providers, the Lumedica Vision device will be the very first OCT screening instrument they’ve been able to afford. They’ll love the price. They’ll love its portability. And the fact that they’ll finally be able to detect eye disease earlier than ever.
Int'l Opthamologists & Optometrists
High cost has prevented most of the world's eye professionals from using OCT.
U.S. Opthamologists & Optometrists
The low-cost and portability are attractive to providers treating underserved populations.
GP's will be able to screen retinas as part of a routine exam-- especially valuable for aging patients.
Original Equipment Manufacture (OEM)
The compact light engine complements other diagnostic technologies in integrated instruments.
Dr. Adam Wax – Interim CEO
- Professor of Biomedical Engineering in the Pratt School of Duke University
- Inventor of several technologies licensed to Lumedica
- Co-founder and board chairman at OncoScope. Raised $11M+ in capital
Dr. William Brown – CTO
- Co-founder of four companies in medical imaging and telecom
- Part of two successful exits
- Built commercially successful OCT product-line
Beth Hollister, RN – Director of Clinical Regulatory Affairs
- Founded, and sold Piedmont Research Labs
- Clinical Trials Manager Duke University Medical Center
- Clinical Trials Director for Harrier, Glycosan Pharmaceuticals
Lumedica Vision was featured alongside other OCT companies as a gamechanger, redefining how Optical Coherence Tomography could fit into clinical spaces. Read the entire article here.
Lumedica receives NIH-STTR award to investigate a SOCT GI probe alongside Dr. Jatin Roper at Duke University
DURHAM, NORTH CAROLINA – Lumedica Inc. receives a $256,323 NIH-NIBIB Small Business Technology Transfer (STTR) grant to research and develop a low-cost, high-performance, spectroscopic optical coherence tomography (SOCT) device for evaluating colonic polyps during colonoscopy procedures. Lumedica will partner with Duke University and Dr. Jatin Roper to investigate the clinical and commercial feasibility of a […]
DURHAM, NORTH CAROLINA – Lumedica Inc., a privately held company focused on improving access to eye care by creating low-cost, high performance, Optical Coherence Tomography (OCT) systems for research and clinical applications, was awarded Third Place in Pepperdine University’s Graziado Business School annual survey of the Most Fundable Companies. Over 3,500 early-stage companies were evaluated […]
We’ve known since Lumedica’s founding that the low-cost OCT would be an effective and efficient alternative to the currently expensive Optical Coherence Tomography systems currently available for screening eye diseases. Now, Lumedica’s founder and Chief Science Officer, Dr. Adam Wax, has documented the results of a jointly-conducted clinical study between Duke and UNC that compared the OQ […]
DURHAM, NORTH CAROLINA – Lumedica Inc., a privately held company, focused on improving access to eye care by creating low-cost, high performance, Optical Coherence Tomography (OCT) systems for research and clinical applications, received a $1M Phase II NIH-NEI SBIR grant in order to continue system and product development. OCT is considered the gold standard for […]
ROCHESTER, NEW YORK — The Upstate New York economic development program, “Luminate,” which helps incubate and invest in optical technology startups, awarded Lumedica Vision third place in its 2019 competition, which includes a $250,000 funding offer. The ceremony marked the end of an intense six-month business development program in which the Luminate/NextCorp team provided hands-on […]
404 HUNT STREET | SUITE 510
DURHAM, NORTH CAROLINA 27701